COBRRA
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Registration:
Sponsors:
OHRI (Ottawa Hospital Research Institute)
Status:
- Recruiting
- Seeking sites & Collaborators
Design
Open-label RCT (randomized controlled trial) comparing bleeding risk with rivaroxaban versus apixaban for acute treatment of VTE (venous thromboembolism)
Participating Sites
Lead Network:
CanVECTOR
Countries:
Australia & New Zealand, Canada,Lead Investigators
Lana Castellucci, MD, MSc
lcastellucci@toh.caSubscribe